Some states now allow dispensing of oral anticancer medications via practice-based pharmacies. In this segment, Michael Kolodziej, MD, and Ted Okon, MBA, consider the impact of establishing a dispensing pharmacy within a practice.
Dr Kolodziej remarks that although these pharmacies permit patients to receive their medications at their doctor’s office, barriers and concerns including prior authorizations, co-payment costs, and patient adherence remain. Additionally, small practices are not able to negotiate with payers for volume discounts. Comparative effectiveness research could play an important role in addressing some of these issues, suggests Dr Kolodziej.
Many practices have reached out to the Community Oncology Alliance (COA) looking for support and information about operating pharmacies within their practices, notes Mr Okon. To assist practices, the COA recently established the Community Oncology Pharmacy Association to help establish quality standards, among other goals.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More